Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Instem performing well; SEND platform stars

The company has developed software used by the life sciences industry to collate and transmit data
Instem performing well; SEND platform stars
SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration

Instem Plc (LON:INS), the developer of software used by the life sciences industry to collate and transmit data, said first-half trading was in line with market expectations.

The highlight was the performance of its SEND platform, with the value of contracts won thus far in 2018 exceeding the total for all of last year.

In all, it had 103 orders in the first six months from 50 different clients.

Instem said the contracted value of the SEND-related new business was up 190% year-on-year, while the pipeline continues to grow, driven by the US Food & Drug Administration’s investigational new drug rules.

SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration. It ensures that companies present data in a consistent format.

Sending the right message

It said a further shift towards providing its software as a service (rather than making one-off sales), combined with “increasingly material recurring outsourced services revenue”, will see a continued improvement of earnings visibility.

Both its Provantis and Samarind products are accessible via the cloud.

Financially, Instem has a solid base with net cash of £3.7mln at June 30.

"The financial year has started well and we are confident further new business, the delivery of recent contract wins and strong operational management will ensure we meet our expectations for the full year," said chief executive Phil Reason.

Shares more than double in value

The shares, which have more than doubled in value in the year to date, rise 7% in morning trade to change hands for 315p. This values the business at £50mln.

In a note to clients, Progressive Equity said: “In our view, the overall tone of the update is optimistic and the outlook statement positive.”

View full INS profile View Profile

Instem Plc Timeline

Related Articles

Virtual Reality headset
May 02 2018
The integration of the group's Apollo 11 experience into the Oculus Go launch package has seen its share price rocket up over 40%
mobile payment
June 22 2018
MySQUAR wants to beef up the mobile payments side of its operations in anticipation of a surge in demand for those services in a country where only 20% of the adult population have a bank account
Trading screen
June 13 2018
Following a root and branch overhaul, the company is setting its sights firmly on a SaaS business model as it reconnects with its technology pedigree

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use